Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility trial of faecal microbiota transplantation in cirrhosis
2017-003629-13Phase 2Completed
- Sponsor
- King's College London
- Start
- Dec 2017
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Cirrhosis comparing FMT with Placebo (2 arms). Primary endpoints: Feasibility of FMT in advanced cirrhosis and Safety of FMT in advanced cirrhosis. Started Dec 2017; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2017-003629-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003629-13.